tbuckley/cabot-search huggingface dataset:
Annual Report of Health Officer, Port of New York.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. Results from the primary prevention trial in Goteborg, Sweden
Authors: O. Samuelsson
Journal: JAMA (1987)

The relationship of cardiovascular disease (CVD) to the control of blood pressure (BP) and serum cholesterol levels was studied in 686 treated, middle-aged hypertensive men whose condition was followed up for 12 years. Both mean in-study BP (<i>P</i>&lt;.001) and serum cholesterol levels (<i>P</i>&lt;.001) were better predictors for CVD than the respective entry levels (both not significant) in multivariate analysis. Surprisingly, for mean in-study systolic and diastolic BP there seemed to be a level (approximately 150 and 85 mm Hg, respectively) below which further reduction of BP had no additional benefit from treatment. Analyses of CVD morbidity in relationship to changes in BP and serum cholesterol levels clearly showed that a combined reduction of both risk factors was necessary to achieve a substantial reduction in morbidity. These study findings indicate that (1) it may be unfavorable to reduce BP below a certain level in middle-aged hypertensive men; and (2) other risk factor interventions must be improved to improve the patient's prognosis. (<i>JAMA</i>1987;258:1768-1776)
Persistent Lack of Detectable HIV-1 Antibody in a Person With HIV Infection—Utah, 1995
Journal: JAMA (1996)

Infection with human immunodeficiency virus (HIV) is diagnosed routinely by the enzyme immunoassay (EIA) for HIV-1 antibody; a nonreactive blood sample is designated as negative without further testing. However, one limitation of this screening algorithm is that a blood sample may be obtained from a patient with recent HIV infection before detectable HIV antibody is present ("window period"). This report describes a patient with confirmed HIV infection in whom EIAs for HIV antibody (HIV-EIAs) were persistently negative beyond the expected "window period."
To Change or Not to Change
Authors: John P. Hubbard
Journal: JAMA (1971)

For the past two years, the National Board of Medical Examiners has set as the theme for its annual invitational conferences the changes in medical education and the effect of these changes on the nationwide examinations of the board. In the March 1970 conference, students, interns, and residents were included as members of a panel to interact with each other and to respond to questions from the floor; in the March 1971 conference, the panelists were chairmen (past or present) of the board's committees that are responsible for creating the examinations in the basic sciences (morning panel) and the clinical sciences (afternoon panel). A significant similarity appeared between the opinions of the recipients of medical education in 1970 and the providers of medical education in 1971, demonstrating thereby, on the one hand, the present-day sense of responsibility and participation of students in the affairs of the faculty and, on the
Abstract 3434: Selective inhibition of mTORC2 by disruption of mLST8 scaffolding function
Authors: Laura C. Kim, Yoonha Hwang, Wenqiang Song, Rebecca S. Cook, Jin Chen
Journal: Cancer Research (2019)

Abstract Mechanistic target of rapamycin (mTOR) is a serine/threonine kinase that acts in two distinct complexes, mTORC1 and mTORC2, and is dysregulated in many diseases including cancer. mLST8 is a shared component of both mTORC1 and mTORC2, yet little is known regarding how mLST8 contributes to assembly and activity of the mTOR complexes. We assessed mLST8 loss in a panel of normal and cancer cells, finding little to no impact on mTORC1 activity, nor on assembly of mTOR with the mTORC1 co-factor Raptor. However, mLST8 loss blocked mTOR association with the mTORC2 co-factors Rictor and Sin1, and impaired mTORC2 kinase activity, including its phosphorylation of AKT at S473. We identified two sites within mLST8 governing its interaction with mTOR, finding that simultaneous mutation of these sites together, but not individually, disrupted not only mTOR-mLST8 interactions, but also blocked mTOR assembly with Rictor and Sin1, thus disrupting mTORC2 activity. Similary, a single mutation on mLST8 with a corresponding mutation on mTOR interfered with mTORC2 assembly, without affecting mTORC1 assembly or activity. We further discovered a direct interaction between mLST8 and the NH2-terminal domain of the mTORC2 cofactor Sin1. Using PTEN-null prostate cancer xenografts, we found that mLST8 mutations disrupting the mTOR interaction motif inhibited AKT S473 phosphorylation, decreased tumor cell proliferation, and increased tumor cell death in vivo. Together, these data suggest that the scaffolding function of mLST8 is critical for assembly and activity of mTORC2, but not mTORC1, an observation which could enable therapeutic mTORC2-selective inhibition, while sparing the activity of mTORC1. Citation Format: Laura C. Kim, Yoonha Hwang, Wenqiang Song, Rebecca S. Cook, Jin Chen. Selective inhibition of mTORC2 by disruption of mLST8 scaffolding function [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3434.
Nutrition and fitness
Authors: A. P. Simopoulos
Journal: JAMA (1989)

Industrialized societies are characterized by an abundant and palatable food supply and a decrease in physical activity at home, at work, and in transportation as a result of modern technology. The average American has a body mass index of 26.6 kg/m<sup>2</sup>, 20% above desirable body weight.<sup>1</sup>Recent surveys show that the US population is getting heavier and the average energy intake has increased.<sup>2</sup> Obesity—the result of either overnutrition (increased energy intake) or a sedentary life-style (decreased energy expenditure)—is characterized by a number of metabolic changes related to lipid metabolism. Obese individuals have elevated serum cholesterol and triglyceride and lower high-density lipoprotein concentrations. These changes increase one's risk for coronary heart disease. There are also changes in carbohydrate metabolism, such as hyperglycemia, hyperinsulinemia, insulin resistance, and decreased norepinephrine production. These findings are similar to the metabolic abnormalities found in persons with non-insulin-dependent diabetes mellitus. In overweight persons, the
Imatinib mesylate inhibits C-kit and PDGF mediated cell growth <i>in vitro</i> in ovarian cancer
Authors: C. Mundhenke, I. Meinhold-Heerlein, K. H. Stuerner, F. Roesel, C. Schem, F. Hilpert, K. Nagasaki, W. Jonat, N. Maass
Journal: Journal of Clinical Oncology (2004)

3130 Background: Enhanced and altered signaling at tyrosinkinase receptors (TKR) as abl, c-kit and PDGF-R (receptors) influences tumor growth in a number of solid malignancies. The drug Imatinib is able to reduce cell proliferation by blocking these TKR. Expression patterns of TKR and their impact on growth control in ovarian cancer are investigated. Also the potential therapeutic role of Imatinib for ovarian cancer is examined in vitro. Methods:The ovarian cancer cell lines BG-1, HEY, OVCAR 3, OVCAR 8 and SK-OV 3 are screened for abl, c-kit, PDGF-R-α and -β expression by immunohistochemistry and PCR. Cell lines are incubated 3, 5 and 7 days with rising concentrations of single Imatinib, single Paclitaxel and single Paraplatin. Also combinations of Imatinib with Paclitaxel and Imatinib with Paraplatin are used. Finally ovarian cancer cells are incubated with triple combination of Imatinib, Paclitaxel and Paraplatin. After incubation drug sensibility assays (proliferation and apoptosis) are performed. Results:Abl and PDGF-R-β are expressed in all cell lines. PDGF-R-α is deteceted in BG-1, Skov 3, OVCAR 3 and weakly in OVCAR 8. C-kit expression is only detected in Skov-3 and OVCAR 3. High dose Imatinib incubation (>15 μM for 72 h) leads to receptor independent decrease of cell numbers (IC 50) and pro-apoptotic effects in all cell lines. 72 h combinations of low dose Imatinib (≤ 2 μM) with Paraplatin (IC50), as well as triple combination of Imatinib (≤ 2 μM) with Paclitaxel (IC25) and Paraplatin (IC25) show synergistic effects. Imatinib (≤ 2 μM) in combination with Paclitaxel (IC50) has an additive effect. The chemo-sensitizing effect of low dose Imatinib appears to be mediated by multiple factors, but is enhanced in c-kit positive cell lines (OVCAR 3 and Skov-3). Conclusions: High dose Imatinib leads to unspecific growth inhibition in ovarian cancer cell lines. Additive and even synergistic anti-cancer effects of Imatinib are seen in combination with cytostatic drugs as Paraplatin and Paclitaxel. Further interactions of Imatinib with PDGF-R and c-kit need to be investigated. Additional pre-clinical and clinical studies have to be performed to confirm results in vivo. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Pharmaceutical, Germany Novartis Novartis
Radiology
Authors: R. G. Evens
Journal: JAMA (1993)

Radiology continues to benefit from technological improvements by expanding the capabilities of imaging for clinical diagnosis and treatment. While no completely new procedure was accepted for clinical use in 1992, a variety of procedures that were adaptations of recently established technology demonstrated clinical efficacy. Five components of radiology are particularly important: (1) spiral computed tomography (CT), (2) interventional radiology, (3) two adaptations of magnetic resonance imaging (MRI)—magnetic resonance angiography (MRA) and functional MRI, (4) mammography, and (5) economics. Although most observers thought that CT, which was introduced approximately 20 years ago, was a "mature" technology, the major adaptation of spiral CT has renewed clinical interest in the applications of CT. Spiral CT constantly images an anatomical region for as long as 30 seconds while the patient is transported through the detectors, creating a continuum of anatomical imaging. If conventional CT is thought of as an apple sliced in sections, spiral
Realizing potential of MR coronary angiography may ease patients' test load and diagnosis costs
Authors: M. F. Goldsmith
Journal: JAMA (1994)

A "ONE-STOP SHOP where you can get all the information you need about the heart" is being visualized by some forward-looking cardiologists. The medium for this noninvasive message is magnetic resonance (MR) imaging, said speakers at the 66th annual scientific sessions of the American Heart Association (AHA), held in Atlanta, Ga. A dozen years after the enormous potential of MR in many areas of medicine began to be forecast (<i>JAMA</i>. 1982;247: 151-159 and 1984;251:869-877), Gerald M. Pohost, MD, director, Division of Cardiovascular Diseases, University of Alabama School of Medicine, Birmingham, says the now widely distributed $2-million imaging systems are living up to their advance billing. Not very long ago, their efficacy in diagnosing heart disease was in serious question; now, says Pohost, once the magnets are able to be used to their full potential, they will provide not only superior images but substantial cost savings. The reduction in imaging time
Diabetic retinopathy
Authors: William Daughaday, Isaac Boniuk, Stanford Wessler, Louis V. Avioli
Journal: JAMA (1970)

Dr. John Arradondo, Junior Assistant Resident, the Jewish Hospital of St. Louis, and Assistant in Medicine, Washington University School of Medicine: A 39-year-old obese photographer was hospitalized on Sept 11, 1969, with a chief complaint of blurred vision of five months' duration. The patient had been well until 1967 when he noted the gradual onset of polyuria, polydipsia, and weight loss. In April 1969, blurring of vision occurred in the left eye. An inflammatory process in the anterior chamber was observed and the patient was treated successfully with dilatation of the pupils with 10% phenylephrine hydrochloride ophthalmic solution and local steroids. One month later, he noted blurring of vision in the right eye, which responded to the same medications. In July, the patient was admitted to another hospital for severe, cramping pain in the left flank. A diagnosis of diabetes mellitus was made on the basis of an abnormal glucose
Jahresbericht der niederoestereichischen Landes-Irrenanstalten Wien, Ybbs, Klosterneuburg und Kierlsng-Gugging, sowie der sonatigen Anstallen zur Unterbringung geistgestoerter niederoesterreichischen Landespfleglinge pro 1898. Ausgegeben von niederoesterreichiechen Landesausscusse. Wien. Any der kaiserlich-koeniglichen Hof-und Staatsdruckerei, 1891. [Annual Report of the Asylums far the Insane of Lower Austria, for 1890.]
Journal: American Journal of Psychiatry (1892)
Erratum: Pancreatic Cancer Risk and Nutrition-Related Methyl-Group Availability Indicators in Male Smokers
Authors: R. Z. Stolzenberg-Solomon, D. Albanes, F.J. Nieto, T.J. Hartman, J.A. Tangrea, M. Rautalahti, J. Sehlub, J. Virtamo, P.R. Taylor
Journal: JNCI Journal of the National Cancer Institute (1999)
Large deletion of the X-linked lymphoproliferative disease gene detected by fluorescence in situ hybridization
Authors: K Honda, H Kanegane, M Eguchi, H Kimura, T Morishima, K Masaki, G Tosato, T Miyawaki, E Ishii
Journal: American Journal of Hematology (2000)

The X-linked lymphoproliferative disease (XLP) is an inherited immunodeficiency characterized by an abnormal responses to infection with Epstein-Barr virus (EBV), resulting in fatal infectious mononucleosis, hypogammaglobulinemia, virus-associated hemophagocytic syndrome, and malignant lymphoma. Mutations in the gene coding for a T cell-specific SLAM-associated protein (SAP) have been recently identified in XLP patients. We report on a 1-year-old boy representing fulminant hemophagocytic syndrome. He developed high fever, lymphadenopathy, hepatosplenomegaly with liver dysfunction, and pancytopenia with marrow hemophagocytosis. EBV DNA was abnormally increased in the blood. Polymerase chain reaction failed to amplify SAP mRNA and genomic DNA products from the patient' As peripheral blood. A large deletion of the SAP gene was confirmed by fluorescence in situ hybridization (FISH). FISH analysis also disclosed that the patient's mother was a carrier. We conclude that FISH can be useful in the diagnosis of XLP with large deletions of the SAP gene and its carrier state.
Masthead: (Adv. Healthcare Mater. 7/2019)
Journal: Advanced Healthcare Materials (2019)

Citizenship: Wiley's Corporate Citizenship initiative seeks to address the environmental, social, economic, and ethical challenges faced in our business and which are important to our diverse stakeholder groups.Since launching the initiative, we have focused on sharing our content with those in need, enhancing community philanthropy, reducing our carbon impact, creating global guidelines and best practices for paper use, establishing a vendor code of ethics, and engaging our colleagues and other stakeholders in our efforts.
BUDAPEST
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Risk of Ovarian Cancer after Treatment for Infertility
Authors: Alice S. Whittemore
Journal: New England Journal of Medicine (1994)

More and more women are seeking treatment for infertility,1 probably in part because they are postponing childbearing until an age when their ability to conceive is diminished. The number of office visits to U.S. physicians for infertility services rose from 600,000 in 1968 to about 1.6 million in 19842. And more women are using medications that stimulate ovulation; the number of prescriptions for clomiphene dispensed by U.S. pharmacies nearly doubled from 1973 to 19913. In 1988 approximately 2 million women reported previous exposure to fertility drugs4.The increased use of ovulation-stimulating medications has caused concern about their . . .
Prospective phase II study of integrated rehabilitative treatment in oncologic patients with neuromotor damage from vertebral metastases
Authors: M. R. Strada, M. Frascaroli, I. Jedrychowska, R. Palumbo, G. Poggi, A. Bernardo, G. Villani, M. Melazzini, G. Bernardo
Journal: Journal of Clinical Oncology (2004)

8207 Background: Breast, lung and prostate cancer are associated with a high incidence of bone and osteomedullar metastases, often responsible of a neuromotor damage. A prospective study was designed to verify the feasibility and activity of an integrated rehabilitative protocol in pts with neuromotor damage from vertebral metastases. Methods: Treatment was performed throughout the following steps, with short-term objectives: 1) passive stretching of lower limbs; 2) lower limb physiokinesitherapy (PKT); 3) respiratory PKT; 4) neuromotor PKT; 5) overlesional strengthen; 6) ambulatory training to the use of prescribed aids. All pts underwent dependence evaluation by the Barthel index and Quality of Life (QoL) assessment by FACT-G. Results: Forty-five consecutive pts were enrolled and treated: 26 males and 19 females, median age 20 to 79 years (20–40 years: 13 pts; 41–59 years 24 pts; 60–79 years: 8 pts). Primary tumor was breast carcinoma in 21 pts (47%), lung cancer in 12 pts (27%), prostate carcinoma in 8 pts (18%), ependyma, testis, non-Hodgkin lymphoma and multiple myeloma in each one of the remaining 4 pts. Most pts (82%) had received combined chemo-radiotherapy; while radiotherapy and chemotherapy alone were given in 6 and 3 pts, respectively. All the enrolled pts completed the integrated protocol and were valuable for tolerance and response. Treatment compliance was good, with no drop-out; improvement of QoL was observed in 93% of pts (43/45) by FACT-G. At a median follow-up of 12 months (range 6–18) the dependence evaluation according to the Barthel index showed an improvement compared to the basal levels: from total to severe in 31/45 pts (69%), from severe to moderate in 9 (20%), from moderate dependence to autonomy in 5 (11%). Conclusions: Our results show that such an integrated rehabilitative program in metastatic pts with neuromotor damage from vertebral metastases produced a good clinical activity in both preventing the damages following neurological deficit and optimizing the residual motor potentialities, also improving patient QoL throughout the achievement of the best possible autonomy. No significant financial relationships to disclose.
HUMAN STERILIZATION IN GERMANY AND THE UNITED STATES
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sicca syndrome in a patient with toxic reaction to busulfan
Authors: Y. Sidi
Journal: JAMA (1977)

TREATMENT with busulfan may cause various side effects such as "busulfan lung," Addison-like syndrome, posterior capsular cataracts, atypical epithelial cell accumulation in various organs,<sup>1</sup>and probably myasthenia gravis<sup>2</sup>and endocardial fibrosis.<sup>3</sup> We report a patient with chronic myeloid leukemia (CML) who had been continuously treated with busulfan for almost nine years, and in whom busulfan lung, Addison-like syndrome, bilateral posterior cataracts, and severe sicca syndrome were diagnosed. The question is raised as to whether or not the sicca syndrome is associated with the prolonged administration of busulfan. <h3>Report of a Case</h3> A 52-year-old housewife was treated since 1967 with busulfan (0.5 to 6 mg/day) because of CML. The total dose administered until 1975 was 3,990 mg. In 1972, bilateral posterior cataracts were discovered and extracted. In 1973, Addison-like syndrome was diagnosed and in January 1975, complaints and findings typical of busulfan lung were noted. Shortly afterwards, while